Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AngioDynamics, Inc. announced its financial results for the first quarter of fiscal year 2027, reporting net sales of $80.9 million. This reflects a year-over-year growth, indicating the company's effective execution of its strategy in the medical technology sector. The company aims to enhance cancer treatment and restore healthy blood flow in patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • AngioDynamics reported a strong financial performance with $80.9 million in net sales.
  • The company is focused on expanding cancer treatment options and improving patient quality of life.
  • Continued execution in their strategy is driving growth and profitability.

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights   Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million

Frequently Asked Questions

What were AngioDynamics' net sales for Q1 2027?

AngioDynamics reported net sales of $80.9 million for the first quarter of fiscal year 2027.

When did AngioDynamics' fiscal year 2027 Q1 end?

The first quarter of fiscal year 2027 ended on August 31, 2026.

What is AngioDynamics focused on?

AngioDynamics focuses on restoring healthy blood flow and expanding cancer treatment options.

How did AngioDynamics perform year-over-year?

AngioDynamics experienced year-over-year growth in its financial results.

ShareAdd on Google
Tags: ANGO AngioDynamics fiscal year 2027 financial results medical technology net sales
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$54M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RF ablationPhase 2
Non Small Cell Lung Cancer →